Evidence snapshot
Each vial contains 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, totaling 70 mg. These amounts describe the vial contents, not a dose or a measure of effectiveness. Rounded composition used by this site: 45 mg GHK + 5 mg elemental copper + 10 mg BPC-157 + 10 mg TB-500. GHK and copper together make up the 50 mg GHK-Cu portion; copper is not extra. These are assumed nominal amounts, not verified amounts for every batch.
Why it stands out
The blend concept appeals to people interested in both skin appearance and recovery. Its useful research question is whether combining these particular components offers something beyond studying them individually.
How it may work
The proposed roles differ: GHK-Cu interacts with copper and tissue-remodeling processes, BPC-157 is studied in repair models, and thymosin-related material connects to cell migration. Complementary descriptions do not establish synergy in a finished blend.
What studies found
Component research includes copper-peptide collagen experiments, animal BPC-157 injury models and studies of full-length thymosin beta-4. No controlled human trial of the exact listed GLOW 70 combination was identified in this review.
What the evidence means
The formula has an understandable research rationale, but ingredient evidence cannot be added together as a combined success rate. Stability, interactions and the identity of the TB500 component need evaluation in the actual finished product.
Safety and limitations
A combination makes it harder to identify the cause of a reaction. Copper exposure, peptide identity and injectable quality each matter, and long-term safety of this exact blend has not been established.
Current status
This exact blend is not an FDA-approved drug or standardized clinical product. BPC-157 is also named as a prohibited non-approved substance by the World Anti-Doping Agency, which matters for tested athletes. For tested athletes, the 2027 WADA list separately prohibits the listed components BPC-157 and TB-500 at all times.
Common questions
How does GLOW 70 differ from GLOW 50? It contains 20 mg more GHK-Cu per vial: 50 mg instead of 30 mg. BPC-157 and TB-500 remain at 10 mg each. More total material does not establish stronger results; no direct clinical comparison of these blends was identified.
Personal accounts, not clinical results
The linked GLOW/KLOW discussion focuses on skin goals and whether a blend offers an advantage over GHK-Cu alone. It reflects community interest, not verified results for Signal Axiom's exact formula or proof that more ingredients work better.